DOCSLIB.ORG

University of Cincinnati

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
University of Cincinnati UNIVERSITY OF CINCINNATI DATE: October 19, 2002 I, Ehab Hamed , hereby submit this as part of the requirements for the degree of: Doctor of Philosophy in: Pharmaceutical Sciences/ Industrial Pharmacy It is entitled: Application and Evaluation of Extended Release Technology To Loop Diuretics Approved by: William Cacini, Ph.D. Pankaj Desai, Ph.D. Myron Gerson, M.D. Ronald Millard, Ph.D. Adel Sakr, Ph.D. APPLICATION AND EVALUATION OF EXTENDED RELEASE TECHNOLOGY TO LOOP DIURETICS A Dissertation submitted to the Division of Research and Advanced Studies of the University of Cincinnati in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY (Ph.D.) in the Department of Pharmaceutical Sciences of the College of Pharmacy 2002 by Ehab Ahmed Mamdouh Hamed B.Sc., Assiut University, Egypt, 1996 Committee Chair: Adel Sakr, Ph.D. Abstract Loop diuretics offer great advantages in treating edematous states associated with congestive heart failure, liver cirrhosis and kidney failure owing to their intense diuretic effect. Evidences suggested the diuretic effect can be exaggerated by careful control of the rate at which loop diuretics are made available to the urinary tubules. If optimally designed, peroral extended release formulation can provide better utilization of the same total dose of loop diuretic, an effect of utmost importance in edematous patients with high resistance to loop diuretics. Bumetanide multiparticulate immediate and extended release formulations were developed and tested in rabbits. A novel multiple response optimization technique based on superimposing contour diagrams was developed and successfully used to optimize bumetanide release. Instability in drug release from multiparticulate formulations after storage warrants in depth investigation of different formulation and processing factors controlling drug release. Curing time, temperature, plasticizer level, coating polymer lipophilicity, and the use of hydrophilic seal coat were explored in this study. The findings proved instability in bumetanide release is attributed to drug migration into the film coat during storage. Careful selection of plasticizer level and curing conditions together with the use of hydrophilic seal coat prevented drug migration and stabilized drug release after storage. When compared to immediate release formulation in rabbits, equivalent amounts of bumetanide were excreted from both formulations yet at different rates. The slow delivery of bumetanide from the extended release formulation improved its diuretic and natriuretic efficiencies within the first day after dosing. The activation of compensatory mechanisms is thought to diminish the response to extended release bumetanide formulation within the second day. While providing comparable diuretic and saliuretic effects to that of immediate release formulation, extended release bumetanide formulation can offer the advantage of avoiding the initial, unpleasant and intense diuretic effect experienced with immediate release formulations. Dedication This dissertation is dedicated to my parents in the utmost appreciation and gratitude for their unconditional love, support and continuous encouragement throughout every step in my life. No words or deeds can ever thank them enough for what they blessed me with. Acknowledgements I would like to thank my dissertation committee: Dr. W. Cacini, Dr. P. Desai, Dr. M. Gerson, Dr. R. Millard, and Dr. A. Sakr for their valuable guidance throughout the course of my research. I wish to express special word of thanks to Dr. A. Sakr, my committee chairman for his support both financially and emotionally. Dr. Sakr dealt with me in a fatherly attitude and provided me with constructive criticism that helped me develop the skills required to fulfill my research needs. It was Dr. Sakr's affection and enthusiasm to Industrial Pharmacy research that brought me to this arena and inspired me with the required endurance to face the day-to-day challenges of my research. It is fair to say that without Dr. Sakr's guidance and support, this work would have never been possible. I would like to thank Dr. R. Millard for his guidance and valuable scientific advice in my animal study. Dr. Millard's shared with me some of his great experience and wisdom that helped me not only in my research studies but also in my life perspective. I find my contact with Dr. Millard very fruitful for the development of my research skills. I would like also to thank Dr. M. Gerson for his confidence in my abilities and the financial support to pursue my research goals. I would like to thank Dr. Desai for providing the fluorescence detector needed for my analytical work. I would like to thank Dr. W. Cacini for providing the chart recorder needed for my analytical work. I would like to thank Dr. M. Kurtzman from the Laboratory Animals Medical Services (LAMS) for his indispensable help in the animal study. I would like to thank Dr. H. Amlal from the department of Nephrology for his help with the urine analysis. I would like to thank Dr. H. Al-Khalidi from Procter and Gamble for his advice regarding the statistical treatment of my data. I would like to acknowledge the generous donation of Eudragit RS 30 D from Rohm America. Special thanks go to Mr. A. Honeycheck for his sincere help and support. Finally, I would like to thank my colleagues in the Industrial Pharmacy Program for their needed friendship, cooperation and understanding. Table of Contents Page 1. Introduction 14 1.1. Definition 14 1.2. Pharmacodynamic Rationale for Formulating Loop 14 Diuretics as Extended Release Dosage Forms 1.3. Rationale for Selecting Bumetanide as Model Drug for the 20 Study 1.4. Peroral Extended Release Formulation Design Strategy 25 1.4.1. Diffusion-Controlled Extended Release Formulations 25 1.4.1.1. Reservoir Devices 25 1.4.1.2. Matrix Devices 26 1.4.2. Dissolution-Controlled Extended Release Formulations 26 1.4.3. Osmotic-Controlled Extended Release Formulations 27 1.4.4. Extended Release Formulation Based on Ion Exchange 28 Resin 1.5. Multiparticulate Drug Delivery System 28 1.5.1. Definition and Advantages 28 1.5.2. Manufacture of Multiparticulate Drug Delivery Systems 29 1.5.2.1. Extrusion/ Spheronization Process 29 1.5.2.2. The Use of Fluid Bed Equipment in Pelletization and 31 Coating of Multiparticulate Drug Delivery Systems 1.5.2.2.1. Types of Fluid Bed Equipment 32 1.5.2.2.1.1. Top Spray Fluid Bed 32 1.5.2.2.1.2. Bottom Spray Fluid Bed (Wurster Coater) 32 1 1.5.2.2.1.3. Tangential Spray Fluid Bed (Rotary Fluid Bed) 34 1.5.2.3. Coating of Multiparticulate Systems 34 1.5.2.3.1. Coating of Multiparticulate Systems Using Aqueous 35 Polymeric Dispersion 1.5.2.3.2. Factors to be Considered in Coating of Multiparticulate 36 Systems in Fluid Bed Equipment 1.5.2.3.2.1. Film Forming Temperature 36 1.5.2.3.2.2. Plasticizers 37 1.5.2.3.2.3. Fluidization Air Temperature 39 1.5.2.3.2.4 Spray Rate 39 1.5.2.4. Curing of Coated Multiparticulate System 40 1.6. Optimization of Drug Release from Coated Multiparticulate 42 Systems Using Statistical Modeling 2. Hypothesis 45 3. Objective 45 4. Specific Aims 45 5. Experiment and Methodology 46 5.1. Materials and Supplies 46 5.2. Equipment 47 5.3. Software 48 5.4. Methods 49 5.4.1. Part I: Development and Optimization of Bumetanide 49 Extended Release Formulations Using Response Surface Methodology and Multiple Response Optimization 5.4.1.1. Layering of Bumetanide onto Nu-pariels Sugar Pellets 49 5.4.1.2. Development of Bumetanide Spectrofluorimetric Analytical 50 Method 2 5.4.1.3. Validation of Bumetanide Analytical Method 53 5.4.1.4. Content Uniformity Assessment 53 5.4.1.5. Coating of Bumetanide-Loaded Pellets 54 5.4.1.6. Testing the Release of Bumetanide from Coated Pellets 55 5.4.1.7. Testing the Effect of Dissolution Media pH on the Release 58 of Bumetanide from Coated Pellets 5.4.1.8. Testing the Effect of Agitation Speed on the Release of 58 Bumetanide from Coated Pellets 5.4.1.9. Statistical Analysis and Optimization of Bumetanide 59 Release 5.4.1.10 Preparation and Statistical Evaluation of the Designed 60 Formulation 5.4.2. Part II: Study of the Effect of Curing Conditions and 61 Plasticizer Level on The Release of Bumetanide from Coated Pellets 5.4.2.1. Statistical Experimental Design 61 5.4.2.2. Coating of Bumetanide-Loaded Pellets 63 5.4.2.3. Curing of Coated Pellets 63 5.4.2.4. Testing the Release of Bumetanide from Cured Coated 65 Pellets 5.4.2.5. Seal Coating with Hydroxypropyl Methyl Cellulose (HPMC 65 LV 100) 5.4.2.6. Coating using a Mixture of Eudragit RS and Eudragit RL 65 5.4.2.7. Use of Sodium Chloride as a Channeling Agent in the 68 Coating Formulation 5.4.2.8. Study the Effect of Storage on the Release of Bumetanide 71 from Coated and Cured Pellets 5.4.2.9. Statistical Analysis 71 3 5.4.3. Part III: Testing Selected Optimized Bumetanide Extended 72 Release Formulation in Laboratory Animals 5.4.3.1. Selection of Animal Model 72 5.4.3.1.1. Reasons for Selecting Rabbit as the Animal Model 72 5.4.3.2. Animal Study Design 76 5.4.3.3. Rationale for the number of rabbits used 77 5.4.3.4. Rabbits Manipulation 79 5.4.3.4.1 Rabbits Restraint 79 5.4.3.4.2. Drug Administration 80 5.4.3.4.3. Sample Withdrawal 80 5.4.3.5. Analysis of Blood and Urine Sample for Bumetanide 81 Contents 5.4.3.5.1. Development of HPLC Analytical Method 81 5.4.3.5.2.
Load more

Recommended publications
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • DIURETICS Diuretics Are Drugs That Promote the Output of Urine Excreted by the Kidneys
    DIURETICS Diuretics are drugs that promote the output of urine excreted by the Kidneys. The primary action of most diuretics is the direct inhibition of Na+ transport at one or more of the four major anatomical sites along the nephron, where Na+ reabsorption takes place. The increased excretion of water and electrolytes by the kidneys is dependent on three different processes viz., glomerular filtration, tubular reabsorption (active and passive) and tubular secretion. Diuretics are very effective in the treatment of Cardiac oedema, specifically the one related with congestive heart failure. They are employed extensively in various types of disorders, for example, nephritic syndrome, diabetes insipidus, nutritional oedema, cirrhosis of the liver, hypertension, oedema of pregnancy and also to lower intraocular and cerebrospinal fluid pressure. Therapeutic Uses of Diuretics i) Congestive Heart Failure: The choice of the diuretic would depend on the severity of the disorder. In an emergency like acute pulmonary oedema, intravenous Furosemide or Sodium ethacrynate may be given. In less severe cases. Hydrochlorothiazide or Chlorthalidone may be used. Potassium-sparing diuretics like Spironolactone or Triamterene may be added to thiazide therapy. ii) Essential hypertension: The thiazides usually sever as primary antihypertensive agents. They may be used as sole agents in patients with mild hypertension or combined with other antihypertensives in more severe cases. iii) Hepatic cirrhosis: Potassium-sparing diuretics like Spironolactone may be employed. If Spironolactone alone fails, then a thiazide diuretic can be added cautiously. Furosemide or Ethacrymnic acid may have to be used if the oedema is regractory, together with spironolactone to lessen potassium loss. Serum potassium levels should be monitored periodically.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: an Overview of Systematic Reviews
    Supplementary Online Content Karmali KN, Lloyd-Jones DM, Berendsen MA, et al. Drugs for primary prevention of atherosclerotic cardiovascular disease: an overview of systematic reviews. JAMA Cardiol. Published online April 27, 2016. doi:10.1001/jamacardio.2016.0218. eAppendix 1. Search Documentation Details eAppendix 2. Background, Methods, and Results of Systematic Review of Combination Drug Therapy to Evaluate for Potential Interaction of Effects eAppendix 3. PRISMA Flow Charts for Each Drug Class and Detailed Systematic Review Characteristics and Summary of Included Systematic Reviews and Meta-analyses eAppendix 4. List of Excluded Studies and Reasons for Exclusion This supplementary material has been provided by the authors to give readers additional information about their work. © 2016 American Medical Association. All rights reserved. 1 Downloaded From: https://jamanetwork.com/ on 09/28/2021 eAppendix 1. Search Documentation Details. Database Organizing body Purpose Pros Cons Cochrane Cochrane Library in Database of all available -Curated by the Cochrane -Content is limited to Database of the United Kingdom systematic reviews and Collaboration reviews completed Systematic (UK) protocols published by by the Cochrane Reviews the Cochrane -Only systematic reviews Collaboration Collaboration and systematic review protocols Database of National Health Collection of structured -Curated by Centre for -Only provides Abstracts of Services (NHS) abstracts and Reviews and Dissemination structured abstracts Reviews of Centre for Reviews bibliographic
    [Show full text]
  • The Effect of Diuretics on Patients with Heart Failure: a Network Meta- Analysis: Diuretics Effect on Heart Failure Patients
    J Pharm Pharm Sci (www.cspsCanada.org) 22, 270 - 280, 2019 The Effect of Diuretics on Patients with Heart Failure: A Network Meta- Analysis: Diuretics Effect on Heart Failure Patients Xingsheng Zhao1, MD; Yu Ren2, MD; Hui Li1, MM; Xi Liu 1, MD 1Cardiology Department and 2Clinical Medical Research Center, Inner Mongolia People’s Hospital, Hohhot, Inner Mongolia Autonomous Region, China. Received, April 10, 2019; Revised, May 6, 2019; Accepted, June 12 2019; Published, June 13, 2019. ABSTRACT - Purpose: We aimed to comprehensively evaluate the curative effect of torasemide, tolvaptan, furosemide and azosemide on patients with heart failure. Methods: Relevant studies were retrieved by searching the electronic databases until May 2018. Quality assessment and data extraction of selected studies were evaluated by two reviewers. Heterogeneity across studies was assessed utilizing the I2 statistic and Q- test, and appropriate effect model was selected to calculate the pooled effect size. Network meta-analysis was conducted and the convergence degree of model was evaluated. Results: A total of 12 studies were enrolled in this study. Significant heterogeneity was not identified across the studies. Significantly greater differences were found in left ventricular ejection fraction (LVEF) for furosemide VS. azosemide, in brain natriuretic peptide (BNP) for furosemide VS. azosemide and furosemide VS. torasemide, and in adverse effects for furosemide VS. torasemide through Meta-analysis of direct comparison. In addition, network meta-analysis results suggested there were no significant differences in adverse effects, mortality, BNP and LVEF among these groups. However, the relatively low mortality and small improvement of BNP and LVEF were found in HF patients treated with torasemide.
    [Show full text]
  • Penetrating Topical Pharmaceutical Compositions Containing N-\2-Hydroxyethyl\Pyrrolidone
    Europaisches Patentamt ® J European Patent Office © Publication number: 0 129 285 Office europeen des brevets A2 (12) EUROPEAN PATENT APPLICATION © Application number: 84200823.7 ©Int CI.3: A 61 K 47/00 A 61 K 31/57, A 61 K 45/06 © Date of filing: 12.06.84 © Priority: 21.06.83 US 506273 © Applicant: THE PROCTER & GAMBLE COMPANY 301 East Sixth Street Cincinnati Ohio 45201 (US) © Date of publication of application: 27.12.84 Bulletin 84/52 © Inventor: Cooper, Eugene Rex 2425 Ambassador Drive © Designated Contracting States: Cincinnati Ohio 4523KUS) BE CH DE FR GB IT LI NL SE © Representative: Suslic, Lydia et al, Procter & Gamble European Technical Center Temseiaan 100 B-1820 Strombeek-Bever(BE) © Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl)pyrrolidone. Topical pharmaceutical compositions comprising a pharmaceutically-active agent and a novel, penetration- enhancing vehicle or carrier are disclosed. The vehicle or carrier comprises a binary combination of N-(2-Hydroxyethyl) pyrrolidone and a "cell-envelope disordering compound". The compositions provide marked transepidermal and per- cutaneous delivery of the active selected. A method of treat- ing certain pathologies and conditions responsive to the selected active, systemically or locally, is also disclosed. TECHNICAL FIELD i The present invention relates to compositions which enhance the utility of certain pharmaceutically-active agents by effectively delivering these agents through the integument. Because of the ease of access, dynamics of application, large surface area, vast exposure to the circulatory and lymphatic networks, and non-invasive nature of the treatment, the delivery of pharmaceutically-active agents through the skin has long been a promising concept.
    [Show full text]
  • Systematic Evidence Review from the Blood Pressure Expert Panel, 2013
    Managing Blood Pressure in Adults Systematic Evidence Review From the Blood Pressure Expert Panel, 2013 Contents Foreword ............................................................................................................................................ vi Blood Pressure Expert Panel ..............................................................................................................vii Section 1: Background and Description of the NHLBI Cardiovascular Risk Reduction Project ............ 1 A. Background .............................................................................................................................. 1 Section 2: Process and Methods Overview ......................................................................................... 3 A. Evidence-Based Approach ....................................................................................................... 3 i. Overview of the Evidence-Based Methodology ................................................................. 3 ii. System for Grading the Body of Evidence ......................................................................... 4 iii. Peer-Review Process ....................................................................................................... 5 B. Critical Question–Based Approach ........................................................................................... 5 i. How the Questions Were Selected ................................................................................... 5 ii. Rationale for the Questions
    [Show full text]
  • Azosemide Is More Potent Than Bumetanide and Various Other Loop
    www.nature.com/scientificreports OPEN Azosemide is more potent than bumetanide and various other loop diuretics to inhibit the sodium- Received: 21 November 2017 Accepted: 14 June 2018 potassium-chloride-cotransporter Published: xx xx xxxx human variants hNKCC1A and hNKCC1B Philip Hampel 1,2, Kerstin Römermann1, Nanna MacAulay 3 & Wolfgang Löscher1,2 The Na+–K+–2Cl− cotransporter NKCC1 plays a role in neuronal Cl− homeostasis secretion and represents a target for brain pathologies with altered NKCC1 function. Two main variants of NKCC1 have been identifed: a full-length NKCC1 transcript (NKCC1A) and a shorter splice variant (NKCC1B) that is particularly enriched in the brain. The loop diuretic bumetanide is often used to inhibit NKCC1 in brain disorders, but only poorly crosses the blood-brain barrier. We determined the sensitivity of the two human NKCC1 splice variants to bumetanide and various other chemically diverse loop diuretics, using the Xenopus oocyte heterologous expression system. Azosemide was the most potent NKCC1 inhibitor (IC50s 0.246 µM for hNKCC1A and 0.197 µM for NKCC1B), being about 4-times more potent than bumetanide. Structurally, a carboxylic group as in bumetanide was not a prerequisite for potent NKCC1 inhibition, whereas loop diuretics without a sulfonamide group were less potent. None of the drugs tested were selective for hNKCC1B vs. hNKCC1A, indicating that loop diuretics are not a useful starting point to design NKCC1B-specifc compounds. Azosemide was found to exert an unexpectedly potent inhibitory efect and as a non-acidic compound, it is more likely to cross the blood-brain barrier than bumetanide. Te Na+–K+–2Cl− cotransporter NKCC1 (encoded by SLC12A2) plays an important role in Cl- uptake in neu- rons both in developing brain and in adult sensory neurons1,2.
    [Show full text]
  • Simultaneous Determination of 5 Diuretic Drugs Using an HPLC Method by Quantitative Analysis of Multiple Components by a Single Marker
    Simultaneous determination of 5 diuretic drugs using an HPLC method by quantitative analysis of multiple components by a single marker Fuchao Chen Hubei University of Medicine Baoxia Fang Hubei University of Medicine Peng Li ( [email protected] ) Hubei University of Medicine Sicen Wang Xi'an Jiaotong University Research Article Keywords: Diuretic drug, Multi-components detection with a single marker, HPLC, Method development Posted Date: April 8th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-397940/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Simultaneous determination of 5 diuretic drugs using an HPLC method by quantitative analysis of multiple components by a single marker Fuchao Chen 1, Baoxia Fang 1, Peng Li 1 *, and Sicen Wang 2 * 1 Sinopharm Dongfeng General Hospital, Hubei University of Medicine, Shiyan, Hubei, 442008, P.R. China. 2 School of Pharmacy, Xi'an Jiaotong University, Xi'an, 710061, Shanxi, PR China. Fu-chao Chen and Baoxia Fang contributed equally to this work and should be considered as equal first authors. Correspondence to: Peng Li, E- mail: [email protected]. Sinopharm Dongfeng General Hospital, Hubei University of Medicine, Shiyan, Hubei, 442008, P.R. China.Sicen Wang, E- mail: [email protected]. School of Pharmacy, Xi'an Jiaotong University, Xi'an, 710061, Shanxi, PR China. Abstract: Background: Loop diuretics are commonly used in clinical practice to manage high fluid loads and to control fluid balance. In this paper, a novel quantitative analysis method for multiple components with a single marker (QAMS) was developed for the simultaneous determination of 5 diuretic drugs furosemide, torasemide, azosemide, etacrynic acid, and bumetanide, by HPLC.
    [Show full text]
  • Tepzz 77889A T
    (19) TZZ T (11) EP 2 277 889 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 26.01.2011 Bulletin 2011/04 C07K 1/00 (2006.01) C12P 21/04 (2006.01) C12P 21/06 (2006.01) A01N 37/18 (2006.01) (2006.01) (2006.01) (21) Application number: 10075466.2 G01N 31/00 C07K 14/765 C12N 15/62 (2006.01) (22) Date of filing: 23.12.2002 (84) Designated Contracting States: • Novozymes Biopharma UK Limited AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Nottingham NG7 1FD (GB) IE IT LI LU MC NL PT SE SI SK TR (72) Inventors: (30) Priority: 21.12.2001 US 341811 P • Ballance, David James 24.01.2002 US 350358 P Berwyn, PA 19312 (US) 28.01.2002 US 351360 P • Turner, Andrew John 26.02.2002 US 359370 P King of Prussia, PA 19406 (US) 28.02.2002 US 360000 P • Rosen, Craig A. 27.03.2002 US 367500 P Laytonsville, MD 20882 (US) 08.04.2002 US 370227 P • Haseltine, William A. 10.05.2002 US 378950 P Washington, DC 20007 (US) 24.05.2002 US 382617 P • Ruben, Steven M. 28.05.2002 US 383123 P Brookeville, MD 20833 (US) 05.06.2002 US 385708 P 10.07.2002 US 394625 P (74) Representative: Bassett, Richard Simon et al 24.07.2002 US 398008 P Potter Clarkson LLP 09.08.2002 US 402131 P Park View House 13.08.2002 US 402708 P 58 The Ropewalk 18.09.2002 US 411426 P Nottingham 18.09.2002 US 411355 P NG1 5DD (GB) 02.10.2002 US 414984 P 11.10.2002 US 417611 P Remarks: 23.10.2002 US 420246 P •ThecompletedocumentincludingReferenceTables 05.11.2002 US 423623 P and the Sequence Listing can be downloaded from the EPO website (62) Document number(s) of the earlier application(s) in •This application was filed on 21-09-2010 as a accordance with Art.
    [Show full text]